Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers
EV demonstrated antitumor activity in patients with predominantly heavily pretreated la/m GEA or ESCC. The predefined threshold for promising antitumor activity was met in patients with ESCC but not in those with GEA. Safety was manageable and consistent with previous reports.
Authors
- Changting Meng (ORCID: https://orcid.org/0000-0002-9438-5719)
- Yuko Kuboki
- H. Hara
- Soichiro Kondo (ORCID: https://orcid.org/0009-0007-0984-1964)
- Mary F. Mulcahy (ORCID: https://orcid.org/0000-0002-6103-0989)
- Satoshi Hamauchi (ORCID: https://orcid.org/0000-0002-9857-2095)
- Jason Kaplan (ORCID: https://orcid.org/0000-0003-3085-7147)
- Steven B. Maron (ORCID: https://orcid.org/0000-0002-8794-130X)
- Ning Jin (ORCID: https://orcid.org/0000-0002-6689-4671)
- Joaquina Baranda (ORCID: https://orcid.org/0000-0002-0917-6307)
- Sheng Liu (ORCID: https://orcid.org/0000-0002-4058-4413)
- Marcin Woźniak (ORCID: https://orcid.org/0000-0001-5676-8076)
- Ryan Dillon (ORCID: https://orcid.org/0000-0002-6817-327X)
- Seema Rao Gorla (ORCID: https://orcid.org/0009-0006-5256-2189)
- F P Gardner
- Seiichiro Mitani (ORCID: https://orcid.org/0000-0003-0033-8741)
- Srinivasu Poondru (ORCID: https://orcid.org/0009-0002-8807-9894)
- Keisho Chìn (ORCID: https://orcid.org/0000-0002-2015-8185)
- Fadi S. Braiteh
Institutions
- Northwestern University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Pfizer (United States) (US)
- Shizuoka Cancer Center (JP)
- Saitama Cancer Center (JP)
- University of Kansas Medical Center (US)
- Aichi Cancer Center (JP)
- National Cancer Center Hospital East (JP)
- Tokyo National Hospital (JP)
- Comprehensive Cancer Centers of Nevada (US)
- Astellas Pharma (United States) (US)
- Japanese Foundation For Cancer Research (JP)
- The Ohio State University (US)
- Kindai University (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105806
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Pfizer
- Seagen
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders